

## Press Release

### S Kant Healthcare Limited

September 25, 2019

### Rating Upgraded



|                                     |   |
|-------------------------------------|---|
| <b>Total Bank Facilities Rated*</b> | Rs. 28.50 Cr.                           |
| <b>Short Term Rating</b>            | ACUITE A2+<br>(Upgraded from ACUITE A2) |

\* Refer Annexure for details

### Rating Rationale

Acuite has upgraded the short-term rating to '**ACUITE A2+**' (read as **ACUITE A two plus**) from **ACUITE A2**' (read as **ACUITE A two**) on the Rs. 28.50 crore bank facilities of S Kant Healthcare Limited (SKHL).

The rating upgrade reflects improvement in operating performance, which is expected to be sustained in the medium term. The capital structure of the group continues to remain healthy coupled with sound liquidity position. The rating continues to draw comfort from established position of S Kant Group and healthy profitability margins. However, the rating is constrained by regulatory risk in domestic and export market and susceptibility of profitability to volatility in raw material prices and forex rates.

Mumbai-based, S Kant Healthcare Limited was incorporated in 1990 and is a part of S K Group, established in 1932 by Mr. Sevantilal K. Shah. The company is engaged in the trading of anti-malarial drugs and active pharmaceutical ingredients (API). Another arm of the S K Group, S K Age Export (SKAE), primarily exports to USA, UK and African countries such as Ghana, Tanzania and Nigeria, among others. The day-to-day operations are managed by Mr. Bharat Shah and Mr. Samir Shah.

### About the Group

Established in 1932, the S K Group consists of S Kant Healthcare Limited (SKHL) and S K Age Export (SKAE). The group specialises in the business of pharmaceuticals. SKHL manufactures antimalarial drugs and active pharmaceutical ingredients (API) at Vapi, Gujarat. SKAE was established in 1990 by Mr. Bharat Shah and Mr. Samir Shah. It is into trading and exporting of formulations and active pharmaceutical ingredients (API).

### Analytical Approach

Acuite has taken a consolidated view of S Kant Health Care Private Limited (SKHL) and S K Age Export (SKAE) referred to as the S K Group. This is due to the strong operational and financial linkages between the two entities and a common management. Extent of consolidation- Full.

### Key Rating Drivers

#### Strengths

#### • Established track record and experienced management

S K Group has an established track record of more than five decades in the pharmaceutical industry. The promoters, Mr. Bharat Shah, Mr. Samir Shah and Mr. Lalit Shah, are the third generation entrepreneurs and have over two decades of experience in the pharmaceutical sector.

#### • Comfortable financial risk profile

The financial risk profile of the group is marked by healthy net worth, low gearing and above average debt protection metrics. The net worth stood at Rs. 81.35 crore in FY2019 (Provisional) as against Rs 57.84 crore in the previous year. The healthy growth in revenue is due to accretion of profits. The same has resulted in comfortable gearing of 0.24 times as on March 31, 2019 (Provisional) as against 0.47 times in the previous year. The debt protection metrics improved marked by interest coverage ratio of 28.89 times and debt service coverage ratio of 20.89 times in FY2019 (Provisional). Acuite expects the financial risk profile of the company to remain at comfortable levels over the medium term backed by steady accruals and no significant debt funded capex plans.

#### • Steady growth in revenue and healthy order book

The group has registered revenue growth of 26.36 per cent growth in revenue with Rs 207.61 crore in FY2019 (Provisional) as against Rs. 164.29 crore in FY2018. The growth is mainly driven by expansion into new markets including Nigeria, which is one of the most populated countries in Africa. The group has been able to successfully register more than 100 brochures in different countries, thereby diversifying its revenue stream. The group has healthy orders in hand amounting to Rs 65.00 crore to be executed in by December 2019. The group has further expanded to EU market and expects the same to drive growth in the medium term. The profitability remained healthy despite marginal decline at 19.58 per cent in FY19 (Provisional) as against 20.04 per cent in the previous year. The net profitability improved from 11.23 per cent in FY2018 to 12.54 per cent in the current year.

#### Weaknesses

#### • Susceptibility of profitability to volatility in raw material prices and regulatory risk

The group's profitability is susceptible to volatility in raw material prices and foreign exchange rates. The group exports over 90 per cent of its output to Denmark, Ghana, Uganda, and Singapore among others. However, the same is mitigated by selectively hedging its risk exposure. Further, the group is also exposed to the regulatory risk associated with export of medical drugs to USA, UK and African countries among other.

#### Rating sensitivity

Scaling up of operations, while maintain healthy profit margin.

#### Liquidity Profile

The liquidity position of the group is strong marked by healthy net cash accruals against its maturing debt obligations. The group generated cash accruals of Rs.25.24 crore to Rs. 30.03 crore during the last three years through 2017-19 (Provisional), against Rs 0.08 crore maturing debt obligations over the same period. The cash accruals of the group are estimated to remain comfortable during 2019-21. The cash credit limit in the group remains utilised at 50-70 per cent during the last 6 months period ended August 2019. Acuite believes that the liquidity of the group is likely to remain strong over the medium term on account of healthy cash accrual and no major repayments over the medium term.

#### About the Rated Entity - Key Financials

|                               | Unit    | FY19 (Prov.) | FY18 (Actual) | FY17 (Actual) |
|-------------------------------|---------|--------------|---------------|---------------|
| Operating Income              | Rs. Cr. | 207.61       | 164.29        | 176.64        |
| EBITDA                        | Rs. Cr. | 40.65        | 32.93         | 37.23         |
| PAT                           | Rs. Cr. | 26.03        | 18.45         | 20.60         |
| EBITDA Margin                 | (%)     | 19.58        | 20.04         | 21.08         |
| PAT Margin                    | (%)     | 12.54        | 11.23         | 11.66         |
| ROCE                          | (%)     | 39.46        | 34.43         | 40.43         |
| Total Debt/Tangible Net Worth | Times   | 0.24         | 0.47          | 0.59          |
| PBDIT/Interest                | Times   | 28.89        | 13.07         | 12.09         |
| Total Debt/PBDIT              | Times   | 0.47         | 0.80          | 0.83          |
| Gross Current Assets (Days)   | Days    | 186          | 197           | 178           |

#### Any other information

Not Applicable

#### Applicable Criteria

- Default Recognition - <https://www.acuite.in/criteria-default.htm>
- Manufacturing Entities - <https://www.acuite.in/view-rating-criteria-4.htm>
- Financial Ratios And Adjustments - <https://www.acuite.in/view-rating-criteria-20.htm>
- Trading Entities - <https://www.acuite.in/view-rating-criteria-6.htm>
- Consolidation of Companies- <https://www.acuite.in/view-rating-criteria-22.htm>

#### Note on complexity levels of the rated instrument

<https://www.acuite.in/criteria-complexity-levels.htm>

### Rating History (Upto last three years)

| Date        | Name of Instrument / Facilities    | Term       | Amount (Rs. Cr.) | Ratings/Outlook                       |
|-------------|------------------------------------|------------|------------------|---------------------------------------|
| 21-Aug-19   | Bills Discounting                  | Short Term | 8.00             | ACUITE A2<br>Issuer not co-operating* |
|             | Bills Discounting                  | Short Term | 11.00            | ACUITE A2<br>Issuer not co-operating* |
|             | Bank guarantee/Letter of Guarantee | Short Term | 3.50             | ACUITE A2<br>Issuer not co-operating* |
|             | Letter of credit                   | Short Term | 6.00             | ACUITE A2<br>Issuer not co-operating* |
| 02-Jun-18   | Bills Discounting                  | Short Term | 8.00             | ACUITE A2<br>(Reaffirmed)             |
|             | Bills Discounting                  | Short Term | 11.00            | ACUITE A2<br>(Reaffirmed)             |
|             | Bank guarantee/Letter of Guarantee | Short Term | 3.50             | ACUITE A2<br>(Reaffirmed)             |
|             | Letter of credit                   | Short Term | 6.00             | ACUITE A2<br>(Reaffirmed)             |
| 02-Mar-2017 | Bills Discounting                  | Short Term | 8.00             | ACUITE A2<br>(Assigned)               |
|             | Bills Discounting                  | Short Term | 11.00            | ACUITE A2<br>(Assigned)               |
|             | Bank Guarantee                     | Short Term | 3.50             | ACUITE A2<br>(Assigned)               |
|             | Letter of Credit                   | Short Term | 5.00             | ACUITE A2<br>(Assigned)               |
|             | Bank Guarantee                     | Short Term | 1.00             | ACUITE A2<br>(Assigned)               |

### \*Annexure – Details of instruments rated

| Name of the Facilities | Date of Issuance | Coupon Rate    | Maturity Date  | Size of the Issue (Rs. Cr.) | Ratings/Outlook          |
|------------------------|------------------|----------------|----------------|-----------------------------|--------------------------|
| Bills Discounting      | Not Applicable   | Not Applicable | Not Applicable | 8.00*                       | ACUITE A2+<br>(Upgraded) |
| Bills Discounting      | Not Applicable   | Not Applicable | Not Applicable | 5.00                        | ACUITE A2+<br>(Upgraded) |
| Post Shipment          | Not Applicable   | Not Applicable | Not Applicable | 2.00                        | ACUITE A2+<br>(Assigned) |
| Bank Guarantee         | Not Applicable   | Not Applicable | Not Applicable | 0.50                        | ACUITE A2+<br>(Upgraded) |
| Letter Of Credit       | Not Applicable   | Not Applicable | Not Applicable | 6.00                        | ACUITE A2+<br>(Upgraded) |
| Letter of Guarantee    | Not Applicable   | Not Applicable | Not Applicable | 0.50                        | ACUITE A2+<br>(Upgraded) |
| Proposed               | Not Applicable   | Not Applicable | Not Applicable | 6.50                        | ACUITE A2+<br>(Upgraded) |

\* includes sublimit cash credit of Rs. 6.00 crore and packing credit of Rs.2.00 crore

## Contacts:

| Analytical  | Rating Desk   |
|---|---|
| <p>Pooja Ghosh<br/>Head- Corporate and Infrastructure Sector Ratings<br/>Tel: 033-66201203<br/><a href="mailto:pooja.ghosh@acuite.in">pooja.ghosh@acuite.in</a></p> <p>Abhishek Dey<br/>Rating Analyst<br/>Tel: 033-66201208<br/><a href="mailto:abhishek.dey@acuite.in">abhishek.dey@acuite.in</a></p> | <p>Varsha Bist<br/>Manager - Rating Desk<br/>Tel: 022-49294011<br/><a href="mailto:rating.desk@acuite.in">rating.desk@acuite.in</a></p> |

## About Acuité Ratings & Research:

Acuité Ratings & Research Limited (*Erstwhile SMERA Ratings Limited*) is a full-service Credit Rating Agency registered with the Securities and Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI), for Bank Loan Ratings under BASEL-II norms in the year 2012. Since then, it has assigned more than 6,000 credit ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Mumbai.

**Disclaimer:** An Acuité rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Acuité ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuité, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuité is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. Acuité ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.acuite.in](http://www.acuite.in)) for the latest information on any instrument rated by Acuité.